J Korean Med Assoc.  2013 May;56(5):425-430.

Pharmacologic management of cardiac arrhythmias

• Nam GB

Abstract

Management of cardiac arrhythmias involves antiarrhythmic drugs (AADs), catheter ablation, pacemakers, and implantable defibrillators. The effects of AADs are mediated by blocking various cardiac ion channels, mostly the cardiac sodium, calcium, or potassium channels. A simple classification of AADs based upon the target sites of drug action is useful for clinical application of AADs for common cardiac arrhythmias. Atrioventricular nodal blocking agents are useful for management of tachycardias with the atrioventricular node as a part of the reentrant circuit. Membrane active AADs are used for tachycardias occurring within the atrium or ventricle. Recent large randomized clinical trials have failed to show any beneficial effects of AADs for reducing cardiac mortality in patients with heart failure and at risk of sudden cardiac death or in patients with atrial fibrillation. In spite of these limitations, AAD medication remains an important initial or adjunctive therapy in the management of cardiac arrhythmias.

Keyword

Anti-arrhythmia agents; Cardiac arrhythmias; Tachycardia

MeSH Terms

Anti-Arrhythmia Agents
Arrhythmias, Cardiac
Atrial Fibrillation
Atrioventricular Node
Calcium
Catheter Ablation
Death, Sudden, Cardiac
Defibrillators, Implantable
Heart Failure
Humans
Ion Channels
Membranes
Potassium Channels
Sodium
Tachycardia
Anti-Arrhythmia Agents
Calcium
Ion Channels
Potassium Channels
Sodium

Reference

1. Zipes DP. Braunwald E, editor. Management of cardiac arrhythmias: pharmacological, electrical, and surgical techniques. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: W. B. Saunders;1997. p. 593–639.

2. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW. CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781–788.

3. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347:1825–1833.

4. Kadish A, Passman R. Mechanisms and management of paroxysmal supraventricular tachycardia. Cardiol Rev. 1999; 7:254–264.

5. Chauhan VS, Krahn AD, Klein GJ, Skanes AC, Yee R. Supraventricular tachycardia. Med Clin North Am. 2001; 85:193–223.